{"id":141,"date":"2020-05-05T05:40:10","date_gmt":"2020-05-05T05:40:10","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=141"},"modified":"2020-05-05T05:40:10","modified_gmt":"2020-05-05T05:40:10","slug":"01-may-2020-tocilizumab-reduced-mortality-in-severe-covid-19-patients","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/01-may-2020-tocilizumab-reduced-mortality-in-severe-covid-19-patients\/","title":{"rendered":"(01 May 2020) Tocilizumab- reduced mortality in severe COVID 19 patients"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p class=\"\"><strong>Effective treatment of severe COVID-19 patients with tocilizumab<\/strong><\/p>\n<p><a href=\"https:\/\/doi.org\/10.1073\/pnas.2005615117\"><strong>https:\/\/doi.org\/10.1073\/pnas.2005615117<\/strong><\/a><\/p>\n<p class=\"\">This is a retrospective study on tocilizumab, an IL6R inhibitor, in treatment of 21 patients with severe and critical COVID-19. Within 5 days after tocilizumab, 15 of the 20 patients (75.0%) had lowered their oxygen intake, and 1 patient needed no oxygen therapy. CT scans manifested that the lung lesion opacity absorbed in 19 patients (90.5%).&nbsp; Clinical data showed that the symptoms, hypoxygenmia, and CT opacity changes were improved immediately after the treatment with tocilizumab in most of the patients, suggesting that tocilizumab could be an efficient therapeutic for the treatment of COVID-19.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Effective treatment of severe COVID-19 patients with tocilizumab https:\/\/doi.org\/10.1073\/pnas.2005615117 This is a retrospective study on tocilizumab, an IL6R inhibitor, in treatment of 21 patients with severe and critical COVID-19. Within 5 days after tocilizumab, 15 of the 20 patients (75.0%)&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/01-may-2020-tocilizumab-reduced-mortality-in-severe-covid-19-patients\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(01 May 2020) Tocilizumab- reduced mortality in severe COVID 19 patients&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,18],"tags":[27],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/141"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=141"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/141\/revisions"}],"predecessor-version":[{"id":142,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/141\/revisions\/142"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=141"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=141"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=141"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}